ФРАНКЛИН Ричард (US),СТЕРН Вильям (US),ВРИХОФ Остин (US)
申请号：
RU2015108678
公开号：
RU2015108678A
申请日:
2013.09.17
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A solid oral dosage form comprising: (a) an angiotensin peptide (1-7)； (b) at least one pharmaceutically acceptable pH-lowering agent； (c) at least one absorption enhancer effective to promote bioavailability angiotensin peptide (1-7) and (d) a protective base. 2. A solid dosage form according to claim 1, characterized in that the solid dosage form is a capsule or tablet. A solid dosage form according to claim 1 or 2, characterized in that the pH lowering agent is citric acid. A solid dosage form according to claim 3, characterized in that citric acid is present in an amount greater than 400 mg. A solid dosage form according to claim 3, characterized in that citric acid is present in an amount greater than 500 mg. A solid dosage form according to claim 3, characterized in that citric acid is present in an amount greater than 50% of the total mass of the solid dosage form. A solid dosage form according to claim 1 or 2, characterized in that the pH-lowering agent is tartaric acid. A solid dosage form according to claim 1 or 2, characterized in that the absorption enhancer is acylcarnitine. A solid dosage form according to claim 8, characterized in that the acyl carnitine is lauryl carnitine. A solid dosage form according to claim 9, characterized in that lauryl carnitine is present in an amount of 50-100 mg. The solid dosage form according to claim 9, characterized in that lauryl carnitine is present in an amount of 5-10% of the total weight of the solid dosage form. A solid dosage form according to claim 1 or 2, characterized in that the protective base is less than 20% of the total mass of solid1. Твердая лекарственная форма для перорального введения, содержащая:(a) пептид ангиотензина (1-7)；(b) по меньшей мере одно фармацевтически приемлемое средство, понижающее рН；(c) по меньшей мере один усилитель абсорбции, эффективный для содействия биодоступности пептида ангиотензина (1-7) и(d) защитную основу.2. Твердая лекарственная форма по п. 1, отличающаяся тем, что тв
